Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Volitionrx (VNRX) over the last 9 years, with Q3 2025 value amounting to $42.4 million.

  • Volitionrx's Total Liabilities rose 2003.91% to $42.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year increase of 2003.91%. This contributed to the annual value of $35.5 million for FY2024, which is 315.16% down from last year.
  • As of Q3 2025, Volitionrx's Total Liabilities stood at $42.4 million, which was up 2003.91% from $41.8 million recorded in Q2 2025.
  • Volitionrx's Total Liabilities' 5-year high stood at $42.4 million during Q3 2025, with a 5-year trough of -$31.2 million in Q1 2021.
  • Over the past 5 years, Volitionrx's median Total Liabilities value was $21.4 million (recorded in 2022), while the average stood at $23.4 million.
  • In the last 5 years, Volitionrx's Total Liabilities crashed by 50526.13% in 2021 and then soared by 16697.97% in 2022.
  • Quarter analysis of 5 years shows Volitionrx's Total Liabilities stood at $9.8 million in 2021, then surged by 119.3% to $21.4 million in 2022, then soared by 71.15% to $36.7 million in 2023, then dropped by 3.15% to $35.5 million in 2024, then rose by 19.41% to $42.4 million in 2025.
  • Its Total Liabilities was $42.4 million in Q3 2025, compared to $41.8 million in Q2 2025 and $37.5 million in Q1 2025.